Mucormycosis Market Highlights
Zygomycosis also known as mucormycosis is a rare infection caused by organisms that belong to a group of fungi called Mucoromycotina. These fungi are typically found in the soil and are associated with decaying organic matter, such as leaves compost piles or rotten wood. The treatments for mucormycosis include the use of amphotericin B therapy. The therapy should be immediately administered due to the rapid spread and high mortality rate of the disease.
The mucormycosis market research report projects the industry size to reach USD 997.93 Million by 2030 at 8.4% CAGR during the forecast period 2022-2030.
There are many types of antifungal treatments available in the market. However, many of them have different side effects and thus, there is a huge opportunity for the manufacturers to develop new drugs. Isavuconazole was recently approved by the FDA to treat invasive aspergillosis and invasive mucormycosis. Many drugs are not prescribed to pregnant women and children. Besides this, there are huge opportunities for the market in developing countries. Thus, the development of new drugs can be a huge opportunity for the growth of the market.
The global mucormycosis market consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas’ mucormycosis market accounted for the largest market share, which can be attributed to the presence of huge patient population, increasing prevalence of fungal diseases, and huge healthcare expenditure. Europe accounted for the second largest market which is followed by Asia Pacific. The companies such as Gilead, Celgene, Amgen, and Biogen accounted for the majority of the share.
Asia Pacific is expected to be the fastest growing region in the mucormycosis market over the forecasted period. The annual prevalence of all-type of mycoses increased.
The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.
The mucormycosis is segmented on the basis of species, diagnosis, treatment, and end-users.
On the basis of the species, the market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others
On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.
On the basis of the treatment, the market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs are further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, flucytosine, and others.
On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.
Some of key players spotlighted in the mucormycosis market report are Abbott Laboratories (U.S.), Biocon Limited (India), Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland), Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.), Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)